Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 18,526–18,550 of 27,380 studies, newest first · page 742 of 1096.

July 2013 25

  1. 2013-07-24

    Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease

    ⚠ Retracted — do not rely on it Genetics Nature

    Key finding: APOE4 carrier status was associated with a consistent transcriptomic shift that broadly resembled the LOAD profile.

  2. 2013-07-24

    A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

    ✓ Peer-reviewed Clinical trials New England Journal of Medicine

    As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability.

  3. 2013-07-24

    Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum

    ✓ Peer-reviewed Tau biomarkers The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

    Key finding: Cross-sectional and longitudinal studies. +3 more findings

  4. 2013-07-24

    Impaired default network functional connectivity in autosomal dominant Alzheimer disease

    ✓ Peer-reviewed Brain scans and imaging Neurology

    Key finding: These findings suggest that DMN fcMRI may prove useful as a biomarker across a wide spectrum of disease, and support the feasibility of DMN fcMRI as a secondary endpoint in upcoming multicenter clinical trials in Alzheimer disease. +1 more finding

  5. 2013-07-23

    Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a critical analysis

    ✓ Peer-reviewed Tau biomarkers Journal of neurology

    Key finding: We found a remarkable alteration in CSF biomarker profile in AD, VaD and in acute ischemic events.

  6. 2013-07-23

    ³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain

    ✓ Peer-reviewed Biomarkers Journal of neuroinflammation

    Key finding: Astrocytosis shows a distinct regional pattern in AD brain compared to fibrillar Aβ, suggesting that different types of astrocytes may be associated with the pathophysiological processes in AD. +2 more findings

  7. 2013-07-22

    Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group

    ✓ Peer-reviewed Clinical safety Sleep medicine

    Key finding: Six inclusion criteria were identified for symptomatic therapy and neuroprotective trials: (1) diagnosis of RBD needs to satisfy the International Classification of Sleep Disorders, second edition, (ICSD-2) criteria; (2) minimum frequency of RBD episodes should preferably be ⩾2 times weekly to allow for assessment of change; (3) if the PD-RBD target population is included, it should be in the early stages of PD defined as Hoehn and Yahr stages 1-3 in Off (untreated); (4) iRBD patients with soft neurologic dysfunction and with operational criteria established by the consensus of study investigators; (5) patients with mild cognitive impairment (MCI); and (6) optimally treated comorbid OSA.

  8. 2013-07-19

    Cognitive decline and oral health in middle-aged adults in the ARIC study

    ✓ Peer-reviewed Long-term cohort studies Journal of dental research

    Key finding: This cohort study of middle-aged adults evaluated associations of six-year change in cognitive function with oral health behaviors and conditions in the Atherosclerosis Risk in Communities (ARIC) study. +3 more findings

  9. 2013-07-18

    The role of the posterior cingulate cortex in cognition and disease

    ✓ Peer-reviewed Brain scans and imaging Brain : a journal of neurology

    Key finding: However, other evidence suggests that the region is highly heterogeneous and may play a direct role in regulating the focus of attention.

  10. 2013-07-18

    3T MRI quantification of hippocampal volume and signal in mesial temporal lobe epilepsy improves detection of hippocampal sclerosis

    ✓ Peer-reviewed Hippocampus size on brain scans AJNR. American journal of neuroradiology

    Key finding: In 3T MRI visually inspected by experts, quantification of hippocampal volume and signal can increase the detection of hippocampal sclerosis in 28% of patients with mesial temporal lobe epilepsy.

  11. 2013-07-18

    The prevalence of dementia in urban and rural areas of China

    ✓ Peer-reviewed Disparities Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: The prevalence of dementia, AD, and VaD among individuals aged 65 years and older were 5.14% (95% CI, 4.71-5.57), 3.21% (95% CI, 2.87-3.55), and 1.50% (95% CI, 1.26-1.74), respectively. +1 more finding

  12. 2013-07-17

    Formation and propagation of tau oligomeric seeds

    ✓ Peer-reviewed Drug development Frontiers in neurology

    Key finding: However, recent studies completed both in vitro and in vivo suggest that intermediate forms of tau, known as tau oligomers, between the monomeric form and NFTs are the true toxic species in disease and the best targets for anti-tau therapies. +1 more finding

  13. 2013-07-17

    The stress response to surgery and postoperative delirium: evidence of hypothalamic-pituitary-adrenal axis hyperresponsiveness and decreased suppression of the GH/IGF-1 Axis

    ✓ Peer-reviewed Clinical safety Journal of geriatric psychiatry and neurology

    Key finding: Hypothalamic-pituitary-adrenal axis hyperresponsiveness and a less frequent suppression of the GH/IGF-1 axis in response to acute stress are possibly involved in delirium pathophysiology. +1 more finding

  14. 2013-07-17

    Health status of UK care home residents: a cohort study

    ✓ Peer-reviewed Cognitive tests and assessment Age and ageing

    Key finding: UK care home residents are often poorly served by existing healthcare arrangements. +3 more findings

  15. 2013-07-17

    Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family

    ✓ Peer-reviewed TREM2 and immune genetics Neurobiology of aging

    Key finding: The same type of mutations has recently been shown to cause frontotemporal dementia (FTD) without the presence of any bone phenotype. +1 more finding

  16. 2013-07-17
  17. 2013-07-16
  18. 2013-07-16

    Preferences and priorities for ongoing and end-of-life care: a qualitative study of older people with dementia resident in care homes

    ✓ Peer-reviewed End-of-life care International journal of nursing studies

    Key finding: For older people living with a diagnosis of dementia, the experience of living and dying in a care home is inextricably linked. +1 more finding

  19. 2013-07-16

    Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers

    ✓ Peer-reviewed Disease mechanisms Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association

    Key finding: The aim of this study was to evaluate levels of certain parameters of oxidative stress and markers of endothelial dysfunction in the blood of 21 AD patients under standard treatment compared with 10 controls, in an attempt to elucidate the contribution of AD to the total oxidative stress status of the patients. +2 more findings

  20. 2013-07-16

    Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis

    ✓ Peer-reviewed Down syndrome and Alzheimer's Journal of neuroinflammation

    Key finding: Down syndrome (DS) is the result of triplication of chromosome 21 (trisomy 21) and is the prevailing cause of mental retardation. +1 more finding

  21. 2013-07-15

    Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease

    ✓ Peer-reviewed Brain scans and imaging Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    Key finding: (18)F-labeled THK-5105 and THK-5117 are promising candidates as PET tau imaging radiotracers. +3 more findings

  22. 2013-07-15

    Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration

    ✓ Peer-reviewed Vascular contributions The Lancet Neurology

    Key finding: We completed a structured process to develop definitions and imaging standards for markers and consequences of SVD. +2 more findings

  23. 2013-07-12

    Melatonin in Alzheimer's disease

    ✓ Peer-reviewed Treatments International journal of molecular sciences

    Key finding: Data from clinical trials indicate that melatonin supplementation improves sleep, ameliorates sundowning and slows down the progression of cognitive impairment in AD patients. +1 more finding

  24. 2013-07-12

    Insights into TREM2 biology by network analysis of human brain gene expression data

    ✓ Peer-reviewed TREM2 and immune genetics Neurobiology of aging

    Key finding: Here we use microarray-based expression data generated from 101 neuropathologically normal individuals and covering 10 brain regions, including the hippocampus, to understand TREM2 biology in human brain. +3 more findings

  25. 2013-07-12

    Amylin deposition in the brain: A second amyloid in Alzheimer disease?

    ✓ Peer-reviewed Risk factors Annals of neurology

    Key finding: Metabolic disorders and aging promote accumulation of amylin amyloid in the cerebrovascular system and gray matter, altering microvasculature and tissue structure. +1 more finding

Browse the library by subject, with the full score breakdown →